Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target Raised to $87.00

Supernus Pharmaceuticals (NASDAQ:SUPN) had its target price increased by Cantor Fitzgerald from $67.00 to $87.00 in a research note issued to investors on Wednesday, Marketbeat.com reports. They currently have an overweight rating on the specialty pharmaceutical company’s stock.

Several other research firms have also recently commented on SUPN. Piper Sandler began coverage on shares of Supernus Pharmaceuticals in a research note on Wednesday. They issued an “overweight” rating and a $47.00 target price for the company. Weiss Ratings lowered Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Friday, October 30th. Zacks Research lowered Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, October 5th. Finally, Wall Street Zen cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Supernus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $63.50.

Supernus Pharmaceuticals Trading Down 2.2%

Shares of Supernus Pharmaceuticals stock traded down $0.58 during mid-day trading on Wednesday, hitting $26.16. 5,911,223 shares of the stock were exchanged, compared to its average volume of 1,089,129. Supernus Pharmaceuticals has a twelve month low of $25.92 and a twelve month high of $42.81. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of 7.31, a price-to-earnings-growth ratio of 1.19 and a beta of 0.52. The company has a 50-day simple moving average of $41.02 and a 200 day simple moving average of $46.81.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.14). The firm had revenue of $208.60 million for the quarter, compared to analysts’ expectations of $217.56 million. Supernus Pharmaceuticals had a positive return on equity of 12.99% and a negative net margin of 5.07%. The business’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.80) earnings per share. Equities research analysts forecast that Supernus Pharmaceuticals will post 3.15 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Dividend Announcement

The business also recently declared a special dividend, which was paid on Friday, November 6th. Investors of record on Friday, October 30th were given a dividend of $8.13 per share.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of hedge funds have recently made changes to their positions in SUPN. BlackRock Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter worth $434,871,000. Bank of America Corp DE acquired a new position in Supernus Pharmaceuticals in the second quarter valued at $28,887,000. Rice Hall James & Associates LLC acquired a new position in Supernus Pharmaceuticals in the second quarter valued at $22,800,000. Bank of New York Mellon Corp purchased a new stake in Supernus Pharmaceuticals during the second quarter valued at about $17,553,000. Finally, Freestone Grove Partners LP purchased a new stake in Supernus Pharmaceuticals during the second quarter valued at about $14,716,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.